Tag: ACT Consortium

ACT Consortium Update

Posted on

 

Upcoming webinars

ACT Canada Support for Promoting Innovative Knowledge Mobilization (KM) of Clinical Trial Findings – Presented by the ACT KM Committee

Join this webinar on February 6 to explore knowledge mobilization for clinical trials in Canada, discover innovative strategies, and learn about the ACT Canada KM Committee’s initiatives and funding opportunities.

REGISTER HERE

CanReview: Advancing Clinical Trials Through a Pan-Canadian Single Research Ethics Review System with Susan Marlin, Donna Lillie & Matthew D’Ascanio

Join this webinar to learn about CanReview, a pan-Canadian initiative streamlining ethics reviews for multi-site clinical trials, enhancing collaboration, expanding access to underserved areas, and increasing Canada’s competitiveness.

The same webinar is offered on two separate dates.

February 18 REGISTER HERE

February 20 REGISTER HERE

CanReview Tactical Teams

The CanReview Collaboration is inviting experienced, passionate people from across Canada’s clinical trials community to help shape the future of trials by volunteering on one of CanReview’s tactical teams and groups. This includes individuals who identify as patient partners/people with lived experience.

Click here for more information on the tactical teams and scope of work. 

Contact info@canreview.ca before February 5 to submit an expression of interest!

Training Award

Applications for the 2025-26 CANSTAT Clinical Trial Biostatistics Fellowship Program are now open!

Applications for this one-year, paid fellowship are welcomed from individuals with MSc. or PhD in statistics, biostatistics, or a relevant health sciences discipline (e.g., public health or epidemiology) with a strong statistical or quantitative background.

Deadline to apply: February 21, 2025 

Click here for more information and to apply!

Upcoming Events

On February 24-26, for the 2025 Clinical Trials Training Summit, four Clinical Trials Training Programs – CTTPs (CANTRAIN, CAN-TAP-TALENT, STROKECOG, CBITN) unite to address key challenges in the clinical trials ecosystem in Canada and beyond.

Join us virtually or in-person for three motivating days in the company of a unique assembly of participants, ensuring a diverse, cutting-edge dialogue on advancing quality and innovation in clinical trials in Canada and worldwide.

  • To attend in-person, register by January 26 at 11:59pm.  
  • To attend virtually, register anytime.

Save your spot now and visit our Summit website for further details and announcements: https://wecantrain.ca/home/clinical-trials-training-summit-2025/

ACT Consortium Update – Funding Announcement and Call for Proposals

Posted on

 

RFA 5 – Funding Announcement
As part of ACT’s goal to expand Canada’s participation in international trials, they recently hosted a fifth request for applications to bring high impact randomized controlled trials to Canada that are initiated and are led by a non-Canadian country.

We are pleased to announce that CNTN Scientific Operations Committee co-lead Dr. David Collister had a successfully RFA 5 application endorsed by CNTN. His teams application on the Better Evidence And Translation for Calciphylaxis (BEAT-Calci) global platform trial, with Dr. Meg Jardine from the University of Sydney, was ranked as one of the top ten applications awarded to receive ACT funding for this call for proposals .
RFA 6 – Canadian Biotech Call for Proposals
Another key objective of the ACT Consortium is to facilitate collaboration between Canadian biotechnology groups and clinical trialists. Since most biotechnologies require RCTs demonstrating efficacy and safety to obtain regulatory approvals in Canada, the objective of this RFA is to fund trials evaluating products from Canadian-controlled biotechnology companies in partnership with ACT Network clinical trialists.

Applicants can request up to $400,000 (CAN) in funding to facilitate phase 2, pilot, or Vanguard trials.  Trials that assess safety, recruitment potential, and feasibility are also welcome provided they are an RCT.

Eligibility:

For an application to be eligible, it must fulfill the following criteria.

  • Trial must evaluate a biotechnology from a Canadian-controlled biotechnology company.
  • The proposal must be an RCT and not a product validation observational study.
  • The proposed budget must be CIHR eligible.

 Deadline: The deadline to apply is Sunday January 5th, 2025 at 11:59 pm ET

Application Process:

The application portal can be found here: https://redc.phri.ca/redcap/surveys/?s=LDWA7RLTFJWLNNEM

If you have any questions about the applications process, please reach out to us at: ACT.Canada@PHRI.ca

Should you have any questions or require assistance, please reach out by December 20, 2024 to ensure a prompt response. Queries received after this date may not garner a response.

ACT seeking post-doctoral fellow

Posted on

 

 

 

 

 

 

The Patient Engagement Committee of the Accelerating Clinical Trials Consortium is hiring a post-doctoral fellow for 2 years.

 

The successful candidate will work daily as part of the ACT Consortium Patient Engagement Working Group to lead several key projects that will contribute to and support patient engagement in clinical trials across Canada. The ACT Consortium’s Patient Engagement Working Group brings together patients, caregivers, clinicians, and researchers with expertise in patient engagement in clinical trials. Patient engagement in clinical trials refers to partnering with patients and caregivers (often called “patient partners”) at various clinical trial steps.

 

The Post-doctoral Fellow will work to understand the current landscape of patient engagement in Canadian clinical trials (including existing resources and frameworks) and undertake a needs assessment to determine gaps/areas of need to support patient engagement in the design and conduct of clinical trials in Canada.

 

For more details or to apply, please visit https://www.ohri.ca/Careers/Details.aspx?CareerID=2957

Celebrating Success: Two CNTN endorsed trials selected for funding by CIHR’s ACT Consortium

Posted on

Congratulations to the two nephrology trials selected for funding by the Accelerating Clinical Trials (ACT) Consortium!

 

The objective of this request for applications was to fund partnerships with Canadian-controlled biotechnology companies and ACT/AEC Network clinical trialists. The consortium received 30 applications and selected 6 projects for funding up to $400,000 each.

Each proposal underwent a targeted peer review process where each application was reviewed by a total of 10 independent reviewers – 5 reviewers with experience in clinical trials and 5 reviewers with experience in biotechnology.

We are proud to announce that 2 of the 6 projects selected were endorsed by CNTN.

 

Dr. Michael Walsh, 
Dr. Peter Margetts, 
Dr. Pavel Roshanov – EQUAL Dialysis: Evaluation of Qidni Urea And metabolite cLearance in maintenance Dialysis

Biotech: Qidni

 

Dr. Matthew James, Dr. Neesh Pannu, Dr. Daniel Muruve – PONTIAC: Prevention of Nephrotoxin-induced AKI with Cilastatin Trial

Biotech: Arch Biopartners Inc. 

 

 

You can see the full list of awarded trials here

The ACT Consortium was established to advance and facilitate the implementation of high-quality, high-impact randomized controlled trials (RCTs) to improve global health. For more information on the consortium, visit www.act-aec.com.

Celebrating Success: Two CNTN endorsed trials selected for funding by CIHR’s ACT Consortium

Posted on

Congratulations to Drs. Sam Silver, Amber Molnar and Ann Young and teams for being selected for funding by the Accelerating Clinical Trials (ACT) Consortium! Stream 1 for this request for applications was dedicated to novel trial designs. With a total funding pool of $1.5 million, 2 of the 8 trials selected were CNTN endorsed trials:

 

Dr. Samuel Silver (Kingston, ON; Queens University) and Dr. Amber Molnar (Hamilton, ON; McMaster University): Dial-Bicarb: The Dial-Bicarb Trial investigates dialysate bicarbonate levels
 

Dr. Ann Young (Toronto, ON; Unity Health Toronto and St. Michael’s Hospital): KidneyCare Outreach: Vanguard phase of a population-based randomized clinical trial to strengthen kidney care delivery for patients at high risk of kidney failure

 

You can see the full list of awarded trials here

The ACT Consortium was established to advance and facilitate the implementation of high-quality, high-impact randomized controlled trials (RCTs) to improve global health. For more information on the consortium, visit www.act-aec.com.

Celebrating Success: Two CNTN endorsed trials selected for funding by CIHR’s ACT Consortium

Posted on

Congratulations to Dr. Michael Walsh and Dr. Amit Garg and teams for being selected for funding by the Canadian Institutes for Health Research (CIHR)’s Accelerating Clinical Trials (ACT) Consortium! Of the 43 trials that applied for funding, 2 of the 11 trials selected were CNTN endorsed trials: 

 

Dr. Amit Garg (London, ON; Western University and the London Health Sciences Centre): Effect of a Multi-Component Quality Improvement Intervention on Patient Access to Kidney Transplantation and Living Kidney Donation (EnAKT-LKD)
 

Dr. Michael Walsh (Hamilton, ON; McMaster University and the Population Health Research Institute): Aldosterone blockade for Health Improvement Evaluation in End-stage renal disease (ACHIEVE) 

 

The ACT Consortium was established to advance and facilitate the implementation of high-quality, high-impact randomized controlled trials (RCTs) to improve global health. For more information on the consortium, visit www.act-aec.com.
 

This most recent call for proposals was designed to support ongoing and active, Canadian-led, high-impact RCTs that required additional funding for successful completion. All recipients of this ACT grant will publicly report their results by January 15, 2025. 

 

We look forward to learning their results!